TYPHIM VI Drug Profile
Summary for Tradename: TYPHIM VI
| High Confidence Patents: | 0 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for TYPHIM VI |
Recent Clinical Trials for TYPHIM VI
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Karolinska Institutet | Phase 1 |
| University Hospital, Linkoeping | Phase 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
Pharmacology for TYPHIM VI
| Physiological Effect | Actively Acquired Immunity |
| Established Pharmacologic Class | Inactivated Salmonella Typhi Vaccine |
| Chemical Structure | Polysaccharides, Bacterial Vaccines, Inactivated Vaccines, Typhoid |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for TYPHIM VI Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for TYPHIM VI Derived from DrugPatentWatch Analysis and Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for TYPHIM VI Derived from Patent Text Search
No patents found based on company disclosures
TYPHIM VI Market Dynamics, Financial Trajectory, Patent Status, and Competitive Outlook
Typhim Vi is a Sanofi injectable typhoid vaccine based on purified Vi capsular polysaccharide. Its commercial position is mature rather than high-growth. Demand is tied to international travel, military and humanitarian deployment, institutional vaccination, and typhoid activity in endemic markets. Sanofi does not publicly report Typhim Vi revenue, unit sales, or operating margin separately, so the product’s financial trajectory must be assessed through market drivers, portfolio disclosures, regulatory status, and competition.
What is Typhim Vi and how is it used?
Typhim Vi is an injectable, unconjugated Vi polysaccharide vaccine for prevention of typhoid fever caused by Salmonella enterica serovar Typhi. In the United States, it is approved for individuals two years of age and older and is administered as a single intramuscular dose at least two weeks before expected exposure. Revaccination is recommended every two years for people who remain at risk.[1]
| Attribute | Typhim Vi profile |
|---|---|
| Manufacturer | Sanofi |
| Active component | Purified Vi capsular polysaccharide |
| Dosage form | Injectable vaccine |
| U.S. regulatory status | FDA-approved prescription vaccine |
| U.S. NDA | NDA 019547 |
| Primary use | Pre-travel and exposure-risk vaccination |
| Target population | Adults and children age two years and older |
| Administration | Single intramuscular dose |
| Routine U.S. childhood use | No |
| Protection duration | Limited; revaccination generally every two years |
| Product class | Unconjugated polysaccharide typhoid vaccine |
Typhim Vi does not treat typhoid infection. It is a preventive product, and vaccination does not replace food, water, and hygiene precautions.
What is the market outlook for Typhim Vi?
The market outlook is stable in established travel-vaccine channels but structurally pressured by newer typhoid conjugate vaccines. Typhim Vi retains advantages in regulatory familiarity, global distribution, physician awareness, and adult travel use. Its principal weaknesses are limited duration of protection, lack of strong immunogenicity in children under two, and lower strategic value in national immunization programs compared with typhoid conjugate vaccines.
The main demand drivers are:
- International travel to South Asia and other typhoid-endemic regions.
- Travel-clinic and occupational vaccination.
- Military, aid-worker, and humanitarian deployments.
- Outbreak response and public-sector procurement.
- Continued antibiotic resistance, which increases the value of prevention.
- Periodic shortages or supply interruptions affecting competing vaccines.
The principal market constraints are:
- Typhoid vaccination is concentrated among travelers and high-risk groups rather than the full population.
- Travelers often purchase vaccination only when required by destination-specific risk assessments.
- Typhoid conjugate vaccines are increasingly preferred for children and endemic-country programs.
- Sanofi’s product is a mature vaccine without an obvious patent-based price premium.
- Vaccine demand can decline sharply when international travel falls, as occurred during the COVID-19 period.
The commercial market is therefore more likely to produce recurring, moderate demand than rapid revenue expansion.
How does Typhim Vi compare with competing typhoid vaccines?
Typhim Vi competes with injectable polysaccharide vaccines, oral live vaccines, and newer typhoid conjugate vaccines.
| Product or class | Technology | Typical commercial advantage | Limitation relative to Typhim Vi |
|---|---|---|---|
| Typhim Vi | Vi polysaccharide injection | Established travel-clinic product; single dose | Shorter protection; limited use in children under two |
| Vivotif | Oral live attenuated vaccine | Oral administration; useful for some travelers | Multi-dose regimen; storage and adherence requirements; not suitable for all patients |
| Typbar-TCV | Vi conjugate vaccine | Use in younger children; longer-lasting immune response; public-sector suitability | Different regulatory and procurement profile; higher programmatic complexity |
| Other Vi polysaccharide vaccines | Injectable polysaccharide | Price competition and regional availability | May lack Typhim Vi’s brand recognition or distribution reach |
The most important strategic comparison is with typhoid conjugate vaccines, particularly Typbar-TCV from Bharat Biotech. The World Health Organization has recommended typhoid conjugate vaccines for routine use in endemic areas and outbreak settings because they can be administered to younger children and provide more durable protection than unconjugated polysaccharide vaccines.[2]
Typhim Vi remains better aligned with adult travel medicine than with large-scale childhood immunization programs.
What is the FDA regulatory status of Typhim Vi?
Typhim Vi is FDA-approved under NDA 019547. The U.S. label covers active immunization against typhoid fever for adults and children two years of age and older.[1]
The FDA-approved product has several practical limitations:
- It is not indicated for children younger than two years.
- Protective antibody levels develop after vaccination but are not guaranteed to prevent all infection.
- Protection is incomplete and does not eliminate the need for food and water precautions.
- Revaccination is generally needed every two years for continuing exposure.
- It is a prescription product in the United States.
Typhim Vi is not a biologic with biosimilar substitution dynamics comparable to monoclonal antibodies. Vaccines are regulated as biological products, but there is no conventional biosimilar pathway driving substitution for this product.
What is the Orange Book and patent status of Typhim Vi?
Typhim Vi is a mature product with no apparent commercially meaningful U.S. patent exclusivity remaining. The product was approved decades ago, and any original composition, formulation, or manufacturing patents would ordinarily have expired absent an unusual later patent estate.
| IP category | Typhim Vi assessment |
|---|---|
| Original product patents | Expected to be expired |
| Regulatory exclusivity | Expired |
| Orange Book relevance | Limited for current market protection |
| Method-of-use patents | No material current barrier publicly associated with routine typhoid prevention |
| Formulation patents | No publicly evident current U.S. exclusivity that blocks competition |
| Manufacturing know-how | Potentially relevant, but not an exclusivity substitute |
| Biosimilar protection | Not the relevant competitive framework |
Typhim Vi’s defensibility is therefore based on manufacturing capability, regulatory approvals, supply reliability, brand familiarity, and distribution rather than patent protection.
A vaccine manufacturer can retain a commercial advantage through validated production processes, analytical methods, quality systems, strain or raw-material sourcing, and regulatory files. Those assets may slow entry or raise costs for competitors even when patents no longer protect the product. They do not provide the same legal barrier as an unexpired composition-of-matter patent.
Are there Paragraph IV challenges or patent litigation involving Typhim Vi?
No material current Paragraph IV or patent-litigation event is associated with Typhim Vi in the public regulatory profile cited here. Paragraph IV litigation is more common for small-molecule drugs listed in the FDA Orange Book. It is not the principal competitive mechanism for an old injectable vaccine with limited remaining patent protection.
Competition is more likely to arise through:
- New or expanded vaccine approvals.
- Government tenders.
- Hospital and travel-clinic formulary decisions.
- Manufacturing capacity.
- Price and supply reliability.
- Country-specific regulatory registrations.
No public settlement agreement is central to Typhim Vi’s current commercial position. The key risk is commercial substitution, not litigation-driven generic launch.
When does Typhim Vi lose exclusivity?
Typhim Vi has already lost the exclusivity associated with its original regulatory and patent lifecycle. Its current market protection is practical rather than statutory.
The relevant timeline is:
| Period | Commercial significance |
|---|---|
| 1990s | FDA approval and establishment in the U.S. travel-vaccine market |
| 2000s-2010s | Mature product with established Sanofi distribution |
| 2020-2021 | Travel disruption reduced travel-vaccine demand |
| 2022 onward | Recovery tied to international travel normalization |
| Current period | Mature, largely non-patent-protected product facing TCV substitution |
Sanofi’s economic exposure is therefore sensitive to volume, procurement pricing, and channel mix. A price increase may support short-term revenue but can accelerate switching to alternative Vi vaccines or oral products.
What drives Typhim Vi’s financial trajectory?
Sanofi does not separately disclose Typhim Vi sales. The product is included within the company’s broader Vaccines business, which contains larger franchises such as influenza, meningococcal, pediatric combination, and booster vaccines.[3]
The financial trajectory is best modeled through five variables:
Travel volume
Typhim Vi has meaningful exposure to travel clinics. Revenue fell during the international travel shutdown and recovered as cross-border travel resumed. Future growth depends more on traveler numbers and destination risk than on population growth in the United States.
Product mix
A shift toward conjugate vaccines can reduce the strategic role of polysaccharide vaccines in endemic-country programs. Typhim Vi is better positioned in adults and travelers, while TCVs are stronger in pediatric and government-funded programs.
Tender pricing
Public-sector procurement is price sensitive. Products competing for tenders may face lower margins than products sold through private travel clinics. Sanofi’s distribution scale can help supply reliability but does not eliminate tender pressure.
Supply continuity
Vaccines are vulnerable to manufacturing interruptions, quality events, and cold-chain constraints. A reliable supply position can preserve share even without patent protection. Conversely, shortages can cause clinicians and procurement agencies to establish alternative suppliers.
Geographic mix
The product’s commercial value differs by region:
| Region | Demand profile |
|---|---|
| United States | Travel clinics, occupational use, military and international travelers |
| Europe | Travel medicine and selected institutional demand |
| Asia-Pacific | Endemic-country demand, travel use, and competition from TCVs |
| Africa | Outbreak response and public-sector vaccination, increasingly oriented toward TCVs |
| Latin America | Travel and targeted risk-based vaccination |
The highest-margin channel is generally private travel medicine. Public-sector sales can provide volume but usually carry greater pricing pressure.
How strong is the Typhim Vi commercial position?
Typhim Vi has a moderate commercial position and a weak patent position.
| Dimension | Assessment |
|---|---|
| Brand recognition | Strong in travel medicine |
| Regulatory maturity | Strong |
| Distribution | Strong through Sanofi’s global vaccine infrastructure |
| Patent protection | Weak or expired |
| Manufacturing barrier | Moderate |
| Pediatric positioning | Weak relative to TCVs |
| Adult traveler positioning | Moderate to strong |
| Public-sector tender position | Moderate, with price pressure |
| Growth profile | Low to moderate |
| Litigation exposure | Low based on the cited public record |
| Substitution risk | Moderate and rising from TCVs |
The product’s most durable advantage is channel fit. Adult travelers often need a convenient, established injectable vaccine before departure. That use case remains relevant even as conjugate vaccines expand in endemic-country programs.
Which companies are challenging Typhim Vi?
The competitive field includes manufacturers of alternative typhoid vaccines rather than companies pursuing a conventional patent invalidation strategy.
Relevant competitors include:
- Bharat Biotech, with Typbar-TCV.
- Emergent BioSolutions, with Vivotif, subject to market availability and regional authorization.
- Regional manufacturers of Vi polysaccharide vaccines.
- Public-sector suppliers of typhoid conjugate vaccines.
- Other manufacturers registered in individual national markets.
Bharat Biotech represents the most important technology-based competitive threat because Typbar-TCV is suitable for younger children and has a stronger position in WHO-supported immunization programs.[2]
The competitive threat to Typhim Vi is less immediate in the adult traveler segment, where injection familiarity and established travel-clinic workflows remain important.
What licensing and manufacturing issues affect Typhim Vi?
No major public licensing transaction is required to explain Typhim Vi’s market position. Sanofi’s control of the product’s regulatory file, manufacturing processes, quality systems, and distribution network is commercially more relevant than external licensing.
Manufacturing barriers include:
- Vi polysaccharide production and purification.
- Consistent antigen characterization.
- Sterility and potency testing.
- Stability and cold-chain compliance.
- Batch-release requirements.
- Regulatory variation across countries.
- Site-change validation and supply continuity.
These barriers can discourage small entrants, but they do not prevent established vaccine manufacturers from competing when the market supports additional capacity.
What generic launch scenarios exist for Typhim Vi?
A traditional generic launch scenario is unlikely to dominate the product’s economics. More realistic scenarios are:
Scenario 1: Stable travel-market demand
International travel remains strong, Typhim Vi retains physician familiarity, and Sanofi preserves share through supply reliability. Revenue grows in line with travel vaccination volume, with limited pricing expansion.
Scenario 2: Gradual erosion
Travel demand remains stable, but competing Vi vaccines and oral vaccination alternatives reduce share. Sanofi maintains the product but experiences declining volume or price pressure.
Scenario 3: Faster TCV substitution
Governments and large institutions shift toward TCVs, especially for children and outbreak control. Typhim Vi remains in travel medicine but loses public-sector volume.
Scenario 4: Supply-led upside
Competitor shortages or regulatory interruptions increase demand for Typhim Vi. The benefit would likely be temporary unless Sanofi converts the additional users into recurring travel-clinic demand.
The base case is a mature product with stable-to-declining structural demand outside travel medicine and periodic volume recovery linked to global mobility.
What is the revenue exposure for Sanofi?
Typhim Vi is unlikely to be financially material to Sanofi at the consolidated-company level. Sanofi reports vaccine sales at portfolio or franchise level rather than disclosing Typhim Vi revenue separately.[3]
Its financial importance is better understood as:
- A recurring contribution to the travel-vaccine portfolio.
- A channel product supporting Sanofi’s travel-health presence.
- A source of incremental vaccine revenue without active patent exclusivity.
- A product with limited ability to materially change Sanofi’s overall earnings.
- A potential hedge against competitor shortages in selected markets.
The product may remain strategically useful even if its absolute revenue is modest because manufacturing infrastructure, sales channels, and regulatory registrations can support related vaccine products.
Key Takeaways
- Typhim Vi is a mature Sanofi injectable typhoid vaccine based on purified Vi polysaccharide.
- FDA approval covers adults and children age two years and older.
- Its core commercial market is travel medicine, not routine childhood immunization.
- Sanofi does not separately disclose Typhim Vi revenue, units, or margin.
- Original patent and regulatory exclusivity are no longer meaningful commercial barriers.
- The main competitive threat is typhoid conjugate vaccination, especially in endemic-country pediatric programs.
- Typbar-TCV has stronger positioning for younger children and public-sector immunization.
- Typhim Vi’s commercial protection comes from brand recognition, distribution, manufacturing controls, and supply reliability.
- The most likely financial trajectory is stable-to-declining structural demand with recovery or upside tied to international travel and competitor supply disruptions.
- Paragraph IV litigation and biosimilar substitution are not central risks for this product.
FAQs
Is Typhim Vi a live vaccine?
No. Typhim Vi is an injectable vaccine made from purified Vi capsular polysaccharide. It is not a live attenuated vaccine.
How long does Typhim Vi protect against typhoid fever?
Protection is limited and is generally considered to require revaccination every two years for people who remain at risk.[1]
Can children under two receive Typhim Vi?
No. The U.S. indication covers individuals age two years and older. Typhoid conjugate vaccines may be better suited to younger children, depending on the country’s approval and immunization policy.
Is Typhim Vi included in Sanofi’s reported vaccine revenue?
Sanofi reports vaccine revenue at broader portfolio levels and does not separately identify Typhim Vi revenue in its principal public financial disclosures.[3]
Is Typhim Vi protected by an active U.S. patent?
Typhim Vi is a mature product, and no commercially meaningful unexpired U.S. patent barrier is apparent from its long market history and public regulatory profile. Its competitive position depends mainly on manufacturing, regulatory compliance, distribution, and brand familiarity.
References
-
U.S. Food and Drug Administration. (2021). Typhim Vi: Prescribing information. Sanofi Pasteur Inc.
-
World Health Organization. (2018). Typhoid vaccines: WHO position paper, March 2018. Weekly Epidemiological Record, 93(13), 153-172.
-
Sanofi. (2024). 2023 universal registration document and annual financial report. Sanofi S.A.
More… ↓
